Cladribine
8,003 views
Oncology Pharm
- Bleomycin
- Dactinomycin, Actinomycin D
- Doxorubicin, Daunorubicin
- Azathioprine, 6-MP
- Cladribine
- Cytarabine
- Busulfan
- Cyclophosphamide, Ifosfamide
- Nitrosoureas
- Paclitaxel
- Vincristine, Vinblastine
- Cisplatin, Carboplatin, Oxaliplatin
- Etoposide, Teniposide
- Irinotecan, Topotecan
- Bevacizumab
- Erlotinib
- Cetuximab, Panitumumab
- Imatinib, Dasatinib
- Rituximab
- Bortezomib, Carfilzomib
- Trastuzumab
- Dabrafenib, Vemurafenib
- Raloxifene and Tamoxifen
- Hydroxyurea
- Procarbazine
Summary
Cladribine is a purine analog that is used to treat hairy cell leukemia. Its incorporation into DNA in place of a purine causes premature breaks, and subsequent halting, of DNA synthesis. It can cause numerous adverse effects such as neurotoxicity, nephrotoxicity, and myelosuppression.
Key Points
- Cladribine
- Mechanism
- Purine analog
- Inhibits DNA polymerase
- Causes DNA strand breaks
- Adenosine analog that is resistant to adenosine deaminase (ADA)
- Purine analog
- Clinical Use
- Hairy cell leukemia
- Adverse Effects
- Nephrotoxicity
- Neurotoxicity
- Myelosuppression
- Mechanism